Jacqueline D. Barrientos, MD, MS, discusses the current treatment landscape for CLL, highlights some of the biggest challenges for physicians, and gives her insight on how to move forward in the field.
Kerry Rogers, MD, discusses the feasibility of a new treatment for tumor lysis syndrome and what research still needs to be done with these agents in chronic lymphocytic leukemia.
With newer agents approved for patients with chronic lymphocytic leukemia, physicians are now challenged with how best to utilize them.
Antibody-drug conjugates represent a targeted class of agents with an improved therapeutic index over traditional chemotherapy in the treatment of non-Hodgkin lymphoma.
The combination of duvelisib and fludarabine-cyclophosphamide-rituximab demonstrated efficacy as a frontline treatment for younger patients with chronic lymphocytic leukemia.
The combination of obinutuzumab and chlorambucil reduced the risk of death by 24% versus rituximab plus chlorambucil in treatment-naïve patients with chronic lymphocytic leukemia with comorbidities.
The FDA has granted a regular approval to venetoclax for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, with or without 17p deletion, following at least 1 prior therapy. The BCL-2 inhibitor is now also approved for use in combination with rituximab in the same patient population.
The frontline combination of ibrutinib and venetoclax demonstrated a 100% objective response rate for patients with chronic lymphocytic leukemia, with 77% of patients testing negative for minimal residual disease in the peripheral blood after 6 cycles.
Frontline treatment with the combination of ibrutinib (Imbruvica) and obinutuzumab (Gazyva) improved progression-free survival compared with chlorambucil plus obinutuzumab in patients with CLL or SLL.
Ryan W. Jacobs, MD, discusses the use of small molecule inhibitors in the treatment of patients with chronic lymphocytic leukemia.